What is Ginkgo Bioworks's payments to notes receivables?

Ginkgo Bioworks (DNA) reported payments to notes receivables of $0 in Q4 2025.

What does payments to notes receivables mean?

Captures cash outflows used to purchase debt instruments or provide financing to third parties. This metric indicates the company's strategy for deploying excess capital into credit-based investments rather than core operations. It helps investors understand the company's role as a lender or strategic financier within its ecosystem.

Ginkgo Bioworks DNA Payments to notes receivables

Payments to notes receivables at other companies

Agilent TechnologiesA

$1M—

Emergent BiosolutionsEBS

$0-100%

Other financials

Income statement

See full

Revenue$19.5M-49.1%

Gross profit$16.4M-52.0%

Operating income-$71.4M+11.9%

Net income-$82.6M+9.2%

EPS (diluted)-$1.42+27.6%

Balance sheet

See full

Cash & equivalents$188.7M-46.9%

Total debt$410.7M-5.5%

Total equity$443.2M-31.6%

Total assets$1.0B-20.1%

Cash flow

See full

Operating cash flow-$46.7M+9.4%

CapEx$1.9M-74.6%

Free cash flow-$48.6M+17.8%

Valuation

See full

Market cap$625.16M+24.6%

Enterprise value$847.19M+45.9%

P/S4.4×+2.2×

Profitability

See full

Operating margin-210.7%+7.6pp

Net margin-215.4%+8.3pp

FCF margin-119%-21.2pp

Returns & leverage

See full

Return on equity-55.8%-1.8pp

Debt / equity0.9×+0.3×

Current ratio5.2×+0.3×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireNotesReceivable.

The official record: Ginkgo Bioworks’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ginkgo Bioworks's payments to notes receivables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ginkgo Bioworks's payments to notes receivables?: Ginkgo Bioworks (DNA) reported payments to notes receivables of $0 in Q4 2025.
What does payments to notes receivables mean?: Captures cash outflows used to purchase debt instruments or provide financing to third parties. This metric indicates the company's strategy for deploying excess capital into credit-based investments rather than core operations. It helps investors understand the company's role as a lender or strategic financier within its ecosystem.